Thuja Capital Healthcare Fund invests in TheraSolve N.V.
Utrecht, The Netherlands – Thuja Capital announces today its latest investment, in Therasolve N.V. (Diepenbeek, Belgium). The investment was made from its Thuja Capital Healthcare Fund. Therasolve is a medical device company active in the field of medication adherence. This financing round allows Therasolve to develop and initiate commercialization of its innovative MemoPatch device to enhance treatment adherence.
Dr. Harrold van Barlingen, Managing Partner at Thuja Capital comments: “TheraSolve is built on the fertile soil of a brilliant idea, exactly the right assets, and the right people. We are very pleased that we succeeded in accomplishing this financing round and we are confident that TheraSolve will be successful in developing their first product”.
For more information please refer to the attached press release.